We identified 910 patients with plasma cell disorders from our prospectively maintained database, who had a first attempt at G-CSF-based PBSC mobilization, including MM (565; 62%) or AL (345; 38%), ...
LAKEWOOD, Colo.--(BUSINESS WIRE)-- Terumo BCT has received clearance for the preparation of plasma held at 1° to 6° C within 8 hours and frozen within 24 hours after phlebotomy (PF24) and plasma held ...
Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia(R) Apheresis System at major conferences Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and ...
In recent years, as many of the diseases for which allogeneic HPC transplantation is indicated are associated with advancing age; this therapy has been increasingly offered to patients in their sixth ...
Apheresis, from a Greek word meaning 'to take away', is an alternative to producing blood components from whole blood donations by selectively collecting one or more components directly from donors ...
LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...
Apheresis disposables are expected to dominate the offering segment, with an 83.4% share in 2025. Donor apheresis is expected to register the highest CAGR of 58.2% during the forecast period.
Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results